 Patients with untreated measurable metastatic esophageal cancer were included in this trial. Patients received this combination chemotherapy repeated every 28 days until progression disease. Starting dose dose level 1 were docetaxel 50 mgm2 on day 1, fixed dose intravenously cisplatin 15 mgm2day and continuous infusion 5-FU 800 mgm2day on day 1-4. DLT was defined as follows according to NCI-CTC version 2.0; Grade 4 neutropenia lasting for more than 4days, Grade 4 anemia and thrombocytopenia, Grade 3 neutropenia accompanied fever 38C , and Grade 3 non-hematological toxicity except for nausea, appetite loss , general fatigue. Maximal Tolerated Dose MTD is determined when the incidence of critical toxicity exceeds 50 at a certain dose level. Response rate will be calculated according to RECIST criteria. 